The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug
Open accessAbstract
The rapid development of new anticancer drugs that are safe and effective is a common goal shared by basic scientists, clinicians and patients. The current review discusses one such agent, namely niclosamide, which has been used in the clinic for the treatment of intestinal parasite infections. Recent studies repeatedly identified niclosamide as a potential anticancer agent by various high-throughput screening campaigns. Niclosamide not only inhibits the Wnt/β-catenin, mTORC1, STAT3, NF-κB and Notch signaling pathways, but also targets mitochondria in cancer cells to induce cell cycle arrest, growth inhibition and apoptosis. A number of studies have established the anticancer activities of niclosamide in both in vitro and in vivo models. Moreover, the inhibitory effects of niclosamide on cancer stem cells provide further evidence for its consideration as a promising drug for cancer therapy. This article reviews various aspects of niclosamide as they relate to its efficacy against cancer and associated molecular mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080 · cited 1×
“The activated STAT3 dimers then translocate into the nucleus and activate the transcription of a panel of genes that control cell proliferation, apoptosis, angiogenesis and other cell functions [25, 26].”
Wnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Ginestier, C., Hur, M. H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., Jacquemier, J., Viens, P., Kleer, C. G., Liu, S., et al. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.08.014 · Cited by 4,012
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2499 · Cited by 3,429
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
The NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
Gupta, P. B., Onder, T. T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R. A., & Lander, E. S. (2009) · Cell · doi:10.1016/j.cell.2009.06.034 · Cited by 2,389
TAK1 is a ubiquitin-dependent kinase of MKK and IKK
Wang, C., Deng, L., Hong, M., Akkaraju, G. R., Inoue, J.-I., & Chen, Z. J. (2001) · Nature · doi:10.1038/35085597 · Cited by 2,125
Zhong, Z., Wen, Z., & Darnell, J. E. (1994) · Science · doi:10.1126/science.8140422 · Cited by 2,070
WNT signalling pathways as therapeutic targets in cancer
Anastas, J. N., & Moon, R. T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3419 · Cited by 1,911
Linking Colorectal Cancer to Wnt Signaling
Bienz, M., & Clevers, H. (2000) · Cell · doi:10.1016/s0092-8674(00)00122-7 · Cited by 1,515
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways
Takebe, N., Harris, P. J., Warren, R. Q., & Ivy, S. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.196 · Cited by 992
Chong, C. R., & Sullivan, D. J. (2007) · Nature · doi:10.1038/448645a · Cited by 983
Molecular Basis of NF-κB Signaling
Napetschnig, J., & Wu, H. (2013) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-083012-130338 · Cited by 933
Patrawala, L., Calhoun, T., Schneider-Broussard, R., Zhou, J., Claypool, K., & Tang, D. G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0592 · Cited by 903
Amino acid signalling upstream of mTOR
Jewell, J. L., Russell, R. C., & Guan, K.-L. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3522 · Cited by 894
Shuai, K., Horvath, C. M., Huang, L. H. T., Qureshi, S. A., Cowburn, D., & Darnell, J. E. (1994) · Cell · doi:10.1016/0092-8674(94)90357-3 · Cited by 807
WNT Signaling Pathway and Stem Cell Signaling Network
Katoh, M., & Katoh, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2316 · Cited by 796
Chen, F., Castranova, V., Shi, X., & Demers, L. M. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.1.7 · Cited by 718
NF-κB and cancer — identifying targets and mechanisms
Naugler, W. E., & Karin, M. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.01.020 · Cited by 636
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., Ohtsuka, T., Zhang, H., Mountz, J. D., Koopman, W. J., Kimberly, R. P., et al. (2001) · Nature Medicine · doi:10.1038/91000 · Cited by 543
Croker, A. K., Goodale, D., Chu, J., Postenka, C., Hedley, B. D., Hess, D. A., & Allan, A. L. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00455.x · Cited by 525
Targeting Hedgehog — a Cancer Stem Cell Pathway
Merchant, A. A., & Matsui, W. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2846 · Cited by 500
Target Identification for Small Bioactive Molecules: Finding the Needle in the Haystack
Ziegler, S., Pries, V., Hedberg, C., & Waldmann, H. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201208749 · Cited by 466
Targeting Notch to Target Cancer Stem Cells
Pannuti, A., Foreman, K., Rizzo, P., Osipo, C., Golde, T., Osborne, B., & Miele, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2823 · Cited by 450
Notch Signaling, γ-Secretase Inhibitors, and Cancer Therapy
Shih, I.-M., & Wang, T.-L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3958 · Cited by 421
mTOR signaling and drug development in cancer
Dancey, J. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.21 · Cited by 417
The evolving concept of cancer and metastasis stem cells
Baccelli, I., & Trumpp, A. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201202014 · Cited by 412
Rational targeting of Notch signaling in cancer
Rizzo, P., Osipo, C., Foreman, K., Golde, T., Osborne, B., & Miele, L. (2008) · Oncogene · doi:10.1038/onc.2008.226 · Cited by 395
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
Steelman, L. S., Abrams, S. L., Whelan, J., Bertrand, F. E., Ludwig, D. E., Bäsecke, J., Libra, M., Stivala, F., Milella, M., Tafuri, A., et al. (2008) · Leukemia · doi:10.1038/leu.2008.26 · Cited by 385
Salinomycin as a Drug for Targeting Human Cancer Stem Cells
Naujokat, C., & Steinhart, R. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/950658 · Cited by 351
The biology and toxicology of molluscicides, bayluscide
Andrews, P., Thyssen, J., & Lorke, D. (1982) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(82)90064-x · Cited by 347
Screen for Chemical Modulators of Autophagy Reveals Novel Therapeutic Inhibitors of mTORC1 Signaling
Balgi, A. D., Fonseca, B. D., Donohue, E., Tsang, T. C. F., Lajoie, P., Proud, C. G., Nabi, I. R., & Roberge, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007124 · Cited by 344
Mitochondria as therapeutic targets for cancer chemotherapy
Galluzzi, L., Larochette, N., Zamzami, N., & Kroemer, G. (2006) · Oncogene · doi:10.1038/sj.onc.1209598 · Cited by 337
Jin, Y., Lu, Z., Ding, K., Li, J., Du, X., Chen, C., Sun, X., Wu, Y., Zhou, J., & Pan, J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3950 · Cited by 322
Kim, S.-Y., Kang, J. W., Song, X., Kim, B. K., Yoo, Y. D., Kwon, Y. T., & Lee, Y. J. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.01.007 · Cited by 297
Osada, T., Chen, M., Yang, X. Y., Spasojevic, I., Vandeusen, J. B., Hsu, D., Clary, B. M., Clay, T. M., Chen, W., Morse, M. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3978 · Cited by 271
Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway
Ren, X., Duan, L., He, Q., Zhang, Z., Zhou, Y., Wu, D., Pan, J., Pei, D., & Ding, K. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100146z · Cited by 234
Lu, W., Lin, C., Roberts, M. J., Waud, W. R., Piazza, G. A., & Li, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029290 · Cited by 230 · cited 2×
“Moreover, we recently demonstrated that niclosamide was able to inhibit Wnt/b-catenin signaling by promoting Wnt co-receptor LRP6 degradation, but had no effect on Dvl2 expression in prostate and breast cancer cells [10,11], suggesting that the mechanism underlying niclosamidemediated inhibition of Wnt/b-catenin signa…”
Self-citationSakurai, H., Miyoshi, H., Toriumi, W., & Sugita, T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.15.10641 · Cited by 230
Drugging Wnt signalling in cancer
Polakis, P. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.126 · Cited by 228
Cancer stem cells: In the line of fire
Alison, M. R., Lin, W.-R., Lim, S. M. L., & Nicholson, L. J. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.03.003 · Cited by 225
Engelmann, K., Shen, H., & Finn, O. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2249 · Cited by 216
The Anti-Helminthic Niclosamide Inhibits Wnt/Frizzled1 Signaling
Chen, M., Wang, J., Lu, J., Bond, M. C., Ren, X.-R., Lyerly, H. K., Barak, L. S., & Chen, W. (2009) · Biochemistry · doi:10.1021/bi9009677 · Cited by 213
Stein, U., Arlt, F., Walther, W., Smith, J., Waldman, T., Harris, E. D., Mertins, S. D., Heizmann, C. W., Allard, D., Birchmeier, W., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.08.041 · Cited by 213
Novel Effect of Antihelminthic Niclosamide on S100A4-Mediated Metastatic Progression in Colon Cancer
Sack, U., Walther, W., Scudiero, D., Selby, M., Kobelt, D., Lemm, M., Fichtner, I., Schlag, P. M., Shoemaker, R. H., & Stein, U. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr190 · Cited by 212
Li, M., Khambu, B., Zhang, H., Kang, J.-H., Chen, X., Chen, D., Vollmer, L., Liu, P.-Q., Vogt, A., & Yin, X.-M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.511212 · Cited by 189
Disruption of STAT3 by Niclosamide Reverses Radioresistance of Human Lung Cancer
You, S., Li, R., Park, D., Xie, M., Sica, G. L., Cao, Y., Xiao, Z.-Q., & Deng, X. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0608 · Cited by 182
Li, R., Hu, Z., Sun, S., Chen, Z. G., Owonikoko, T. K., Sica, G., Ramalingam, S. S., Curran, W. J., Khuri, F. R., & Deng, X. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0095 · Cited by 161
Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress
Ketola, K., Hilvo, M., Hyötyläinen, T., Vuoristo, A., Ruskeepää, A.-L., Orešič, M., Kallioniemi, O., & Iljin, K. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.530 · Cited by 159
Fonseca, B. D., Diering, G. H., Bidinosti, M. A., Dalal, K., Alain, T., Balgi, A. D., Forestieri, R., Nodwell, M., Rajadurai, C. V., Gunaratnam, C., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.359638 · Cited by 159
Anticancer Effects of Niclosamide in Human Glioblastoma
Wieland, A., Trageser, D., Gogolok, S., Reinartz, R., Höfer, H., Keller, M., Leinhaas, A., Schelle, R., Normann, S., Klaas, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2895 · Cited by 156
Buchsbaum, D. J., Zhou, T., Grizzle, W. E., Oliver, P. G., Hammond, C., Zhang, S., Carpenter, M., & LoBuglio, A. F. (2003) · PubMed · Cited by 154
Self-citationPavelić, S. K., Stambrook, P. J., & Pavelić, K. (2004) · EMBO Reports · doi:10.1038/sj.embor.7400236 · Cited by 143
Salinomycin: A Novel Anti-Cancer Agent with Known Anti-Coccidial Activities
Zhou, S. Y., Wang, F., Wong, E. T., Fonkem, E., Hsieh, T., WU, J. M., & Wu, E. (2013) · Current Medicinal Chemistry · doi:10.2174/15672050113109990199 · Cited by 141
Pan, J., Ding, K., & Wang, C. (2012) · 癌症:英文版 · doi:10.5732/cjc.011.10290 · Cited by 140
Increased expression of S100A4, a metastasis-associated gene, in human colorectal adenocarcinomas.
Takenaga, K., Nakanishi, H., Wada, K., Suzuki, M., Matsuzaki, O., Matsuura, A., & Endo, H. (1997) · PubMed · Cited by 134
Drug Screening Identifies Niclosamide as an Inhibitor of Breast Cancer Stem-Like Cells
Wang, Y.-C., Chao, T., Chang, C., Yo, Y.-T., Yu, M.-H., & Lai, H.-C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074538 · Cited by 132
Sack, U., Walther, W., Scudiero, D. A., Selby, M., Aumann, J., Lemos, C., Fichtner, I., Schlag, P. M., Shoemaker, R. H., & Stein, U. (2011) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-09-0739 · Cited by 130
Chen, H., Yang, Z., Ding, C., Chu, L., Zhang, Y., Terry, K., Liu, H., Shen, Q., & Zhou, J. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml3003082 · Cited by 122
Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide
Yo, Y.-T., Lin, Y.-W., Wang, Y.-C., Balch, C., Huang, R., Chan, M. W. Y., Sytwu, H., Chen, C.-K., Chang, C., Nephew, K. P., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0002 · Cited by 122
Mutational analysis of acute-phase response factor/Stat3 activation and dimerization
Sasse, J., Hemmann, U., Schwartz, C., Schniertshauer, U., Heesel, B., Landgraf, C., Schneider-Mergener, J., Heinrich, P. C., & Horn, F. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.8.4677 · Cited by 120
Salinomycin – A New Cancer Drug Candidate
Huczyński, A. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01287.x · Cited by 112
Niclosamide: Comprehensive Profile
Al‐Hadiya, B. M. H. (2005) · Profiles of drug substances, excipients, and related methodology · doi:10.1016/s0099-5428(05)32002-8 · Cited by 106
Wang, A., Ku, H., Liang, Y., Chen, Y., Hwu, Y., & Yeh, T. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22065 · Cited by 104
Effect of Niclosamide on Basal-like Breast Cancers
Londoño-Joshi, A. I., Arend, R. C., Aristizabal, L., Lu, W., Samant, R. S., Metge, B. J., Hidalgo, B., Grizzle, W. E., Conner, M., Forero-Torres, A., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0555 · Cited by 97
Self-citationInhibition of STAT3 by Niclosamide Synergizes with Erlotinib against Head and Neck Cancer
Li, R. Q., You, S., Hu, Z., Chen, Z. G., Sica, G., Khuri, F. R., Curran, W. J., Shin, D. M., & Deng, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074670 · Cited by 88
Khanim, F. L., Merrick, B., Giles, H. V., Jankute, M., JACKSON, J. B., Giles, L., Birtwistle, J., Bunce, C. M., & Drayson, M. T. (2011) · Blood Cancer Journal · doi:10.1038/bcj.2011.38 · Cited by 86
Niclosamide induces mitochondria fragmentation and promotes both apoptotic and autophagic cell death
Park, S.-J., Shin, J. H., Kang, H. E., Hwang, J., & Cho, D. (2011) · BMB Reports · doi:10.5483/bmbrep.2011.44.8.517 · Cited by 77
Boudný, V., & Kovařík, J. (2002) · PubMed · Cited by 72
Pharmacokinetics of anti-SARS-CoV agent niclosamide and its analogs in rats
Chang, Y., Yeh, T., Lin, K.-T., et al. (2020) · Journal of Food and Drug Analysis · doi:10.38212/2224-6614.2464 · Cited by 67
Small molecule modulators of Wnt/β-catenin signaling
Mook, R. A., Chen, M., Lü, J., Barak, L. S., Lyerly, H. K., & Chen, W. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.01.101 · Cited by 24
Cited by
Jung, Y.-S., & Park, J.-I. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0380-6 · Cited by 419
“Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway
Bousoik, E., & Montazeri Aliabadi, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00287 · Cited by 376
Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy
Song, P., Gao, Z., Bao, Y., Chen, L., Huang, Y., Liu, Y., Dong, Q., & Wei, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01563-4 · Cited by 382
WNT Signaling in Cardiac and Vascular Disease
Foulquier, S., Daskalopoulos, E. P., Lluri, G., Hermans, K. C. M., Deb, A., & Blankesteijn, W. M. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.013896 · Cited by 347
Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential
Xu, J., Shi, P.-Y., Li, H., & Zhou, J. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00052 · Cited by 340
Metadata
- Authors
- Li, Y., Li, P.-K., Roberts, M. J., Arend, R. C., Samant, R. S., & Buchsbaum, D. J.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 349
- Issue
- 1
- Pages
- 8-14
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2160855995
- Cited by
- 364
- References
- 75
- FWCI
- 10.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.